BUD
MCID: BRL010
MIFTS: 54

Buruli Ulcer (BUD)

Categories: Genetic diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Buruli Ulcer

MalaCards integrated aliases for Buruli Ulcer:

Name: Buruli Ulcer 57 76 53 55 44 73
Buruli Ulcer, Susceptibility to 57 29 13 6 40
Buruli Ulcer Disease 12 53 15
Mycobacterium Ulcerans, Susceptibility to 57
Mycobacterium Ulcerans 57
Bairnsdale Ulcer 12
Daintree Ulcer 12
Searle's Ulcer 12
Mossman Ulcer 12
Searl Ulcer 12
Bud 53

Classifications:



External Ids:

OMIM 57 610446
Disease Ontology 12 DOID:0050456
ICD10 33 A31.1
MeSH 44 D054312
NCIt 50 C84604
SNOMED-CT 68 15845006
UMLS 73 C0085568

Summaries for Buruli Ulcer

OMIM : 57 Buruli ulcer is an infectious disease prevalent in many tropical and subtropical regions caused by infection with Mycobacterium ulcerans. It is the third most frequent mycobacterial disease in humans worldwide, after tuberculosis (607948) and leprosy (246300). Lesions are most common on exposed parts of the body, especially the limbs. Buruli ulcer derives its name from a county in Uganda, East Africa, north of Kampala, where the disease was found in the late 1950s in hundreds of people living near marshes and riverine areas near the Nile River (Clancey et al., 1961; Barker, 1971). The disease was first described in the medical literature in 1948 in a report on patients in Australia (MacCallum et al., 1948). Patients have also been reported from tropical areas in Latin America and Asia (Stienstra et al., 2006; van der Werf et al., 2005). (610446)

MalaCards based summary : Buruli Ulcer, also known as buruli ulcer, susceptibility to, is related to bacterial infectious disease and hemorrhagic fever, and has symptoms including nodule An important gene associated with Buruli Ulcer is SLC11A1 (Solute Carrier Family 11 Member 1), and among its related pathways/superpathways are Innate Immune System and Immune response NFAT in immune response. The drugs Rifampicin and Streptomycin have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and t cells, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in skin or located in subcutaneous tissue, has material basis in Mycobacterium ulcerans, which could be transmitted by insects. The bacterium produces a toxin, named mycolactone, which causes subcutaneous fat necrosis and inhibits an immune response. The infection has symptom nodule, which is a painless, mobile swelling in the skin.

Wikipedia : 76 Buruli ulcer is an infectious disease caused by Mycobacterium ulcerans. The early stage of the infection... more...

Related Diseases for Buruli Ulcer

Diseases related to Buruli Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 269)
# Related Disease Score Top Affiliating Genes
1 bacterial infectious disease 30.2 IFNG IL10 SLC11A1
2 hemorrhagic fever 29.9 CD40LG IFNG IL10
3 leprosy 3 29.9 IFNG IL10 IL4 SLC11A1
4 schistosomiasis 29.8 CD40LG IFNG IL10 IL4
5 mycoplasma pneumoniae pneumonia 29.6 IFNG IL10 IL4
6 aspergillosis 29.6 IFNG IL10 IL4
7 pulmonary tuberculosis 29.5 IFNG IL10 IL4 SLC11A1
8 viral infectious disease 29.3 CD40LG IFNG IL10 IL4
9 rheumatoid arthritis 29.2 CD40LG IFNG IL10 IL4 SLC11A1
10 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.1 CD40LG IFNG IL10 IL4 WAS
11 renal hypodysplasia/aplasia 1 11.3
12 bronchogenic cyst 11.3
13 cephalic disorders 11.1
14 solitary median maxillary central incisor 11.0
15 incisors, fused mandibular 11.0
16 thiourea tasting 11.0
17 liebenberg syndrome 11.0
18 hyperinsulinemic hypoglycemia, familial, 2 11.0
19 optic papillitis 11.0
20 tongue disease 11.0
21 colorectal cancer 10.5
22 mycobacterium marinum 10.5
23 adenocarcinoma 10.3
24 osteomyelitis 10.3
25 cephalosporin allergy 10.3 IFNG IL10
26 oral squamous cell carcinoma 10.2
27 campylobacteriosis 10.2 IFNG SLC11A1
28 chronic graft versus host disease 10.2 IFNG IL10
29 idiopathic achalasia 10.2 IL10 LOC111365141
30 clonorchiasis 10.2 IFNG IL10
31 tuberculoid leprosy 10.2 IFNG IL10
32 squamous cell carcinoma 10.2
33 fungal meningitis 10.2 IFNG IL10
34 chronic active epstein-barr virus infection 10.2 IFNG IL10
35 iron overload in africa 10.2 HBB SLC11A1
36 peanut allergy 10.2 IFNG IL10
37 fascioliasis 10.2 IFNG IL10
38 human immunodeficiency virus type 1 10.2
39 intermediate uveitis 10.2 IFNG IL10
40 extrapulmonary tuberculosis 10.2 IFNG IL10 SLC11A1
41 testicular disease 10.2 IFNG IL10 SLC11A1
42 african tick-bite fever 10.2 CD40LG IFNG
43 lymphadenitis 10.2 IFNG IL10 SLC11A1
44 influenza 10.2
45 post-transplant lymphoproliferative disease 10.2 IL10 SLC11A1
46 ascaridiasis 10.2 IL10 NELFCD
47 plasmodium falciparum malaria 10.2 HBB IFNG IL10
48 tropical endomyocardial fibrosis 10.1 IL10 IL4
49 endomyocardial fibrosis 10.1 IL10 IL4
50 multidrug-resistant tuberculosis 10.1 IL10 SLC11A1

Graphical network of the top 20 diseases related to Buruli Ulcer:



Diseases related to Buruli Ulcer

Symptoms & Phenotypes for Buruli Ulcer

Clinical features from OMIM:

610446

Symptoms:

12
  • nodule

MGI Mouse Phenotypes related to Buruli Ulcer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 ATF4 IFNG IL10 IL4 SLC11A1 WAS
2 endocrine/exocrine gland MP:0005379 9.17 ATF4 CD40LG IFNG IL10 IL4 SEC61A1

Drugs & Therapeutics for Buruli Ulcer

Drugs for Buruli Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rifampicin Approved Phase 2, Phase 3,Phase 3,Not Applicable 13292-46-1 5458213 5381226
2
Streptomycin Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 57-92-1 19649
3
Clarithromycin Approved Phase 2, Phase 3,Phase 3 81103-11-9 84029
4 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Not Applicable
5 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 3,Not Applicable
6 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Not Applicable
7 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Not Applicable
8 Cytochrome P-450 CYP3A Inducers Phase 2, Phase 3,Phase 3,Not Applicable
9 Antitubercular Agents Phase 2, Phase 3,Phase 3,Not Applicable
10 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3,Phase 3
11 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3,Phase 3
12
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
13 Antiparasitic Agents Phase 2
14 Antiprotozoal Agents Phase 2
15 Antimalarials Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 Active, not recruiting NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
2 BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA Completed NCT00321178 Phase 2, Phase 3 SR4 - switch to CR4
3 Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana Completed NCT02281643 Phase 2 Doxycycline
4 Timing of Surgical Intervention in Buruli Ulcer Patients Treated With Antibiotics Unknown status NCT01432925 Not Applicable
5 Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer Active, not recruiting NCT02153034
6 Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia Recruiting NCT03683745

Search NIH Clinical Center for Buruli Ulcer

Cochrane evidence based reviews: buruli ulcer

Genetic Tests for Buruli Ulcer

Genetic tests related to Buruli Ulcer:

# Genetic test Affiliating Genes
1 Buruli Ulcer, Susceptibility to 29 SLC11A1

Anatomical Context for Buruli Ulcer

MalaCards organs/tissues related to Buruli Ulcer:

41
Skin, Bone, T Cells, Lung, Colon, Heart, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Buruli Ulcer:

19
Skin Or

Publications for Buruli Ulcer

Articles related to Buruli Ulcer:

(show top 50) (show all 453)
# Title Authors Year
1
Microdeletion on chromosome 8p23.1 in a familial form of severe Buruli ulcer. ( 29708969 )
2018
2
A severe case of <em>Mycobacterium ulcerans</em> (Buruli ulcer) osteomyelitis requiring a below-knee amputation. ( 29642809 )
2018
3
Laboratory confirmation of Buruli ulcer cases in Ghana, 2008-2016. ( 29870529 )
2018
4
Buruli ulcer. Review of a neglected skin mycobacterial disease. ( 29343539 )
2018
5
A protocol for culturing environmental strains of the Buruli ulcer agent, Mycobacterium ulcerans. ( 29712992 )
2018
6
The incubation period of Buruli ulcer (Mycobacterium ulcerans infection) in Victoria, Australia - Remains similar despite changing geographic distribution of disease. ( 29554096 )
2018
7
Surgery for Buruli ulcer in the antibiotic era. ( 29605497 )
2018
8
Report of a series of 82 cases of Buruli ulcer from Nigeria treated in Benin, from 2006 to 2016. ( 29522516 )
2018
9
Developing a Buruli ulcer community of practice in Bankim, Cameroon: A model for Buruli ulcer outreach in Africa. ( 29584724 )
2018
10
Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial. ( 29605498 )
2018
11
Molecular detection of Mycobacterium ulcerans in the environment and its relationship with Buruli ulcer occurrence in Zio and Yoto districts of maritime region in Togo. ( 29782522 )
2018
12
Implementation of a decentralized community-based treatment program to improve the management of Buruli ulcer in the Ouinhi district of Benin, West Africa. ( 29529087 )
2018
13
Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans. ( 29237707 )
2018
14
Perceived causes and risk factors of Buruli ulcer among patients at Agogo Presbyterian hospital in Ashanti Region of Ghana. ( 29361986 )
2018
15
Comparative genomics shows<i>Mycobacterium ulcerans</i>migration and expansion has preceded the rise of Buruli ulcer in south-eastern Australia. ( 29439984 )
2018
16
Diagnostic Tests for Buruli Ulcer: Clinical Judgment Revisited. ( 29538643 )
2018
17
Subcutaneous Granulomatous Inflammation due to Basidiobolomycosis: Case Reports of 3 Patients in Buruli Ulcer Endemic Areas in Benin. ( 29545962 )
2018
18
Risk factors for Mycobacterium ulcerans infection (Buruli Ulcer) in Togo a98 a case-control study in Zio and Yoto districts of the maritime region. ( 29351741 )
2018
19
<i>In Silico</i> Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa. ( 29954088 )
2018
20
Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response. ( 29642808 )
2018
21
Diagnostic Accuracy of Clinical and Microbiological Signs in Patients with Skin Lesions Resembling Buruli Ulcer in an Endemic Region. ( 29538642 )
2018
22
Perception and incidence of Buruli ulcer in Ogun State, South West Nigeria: intensive epidemiological survey and public health intervention recommended. ( 30050630 )
2018
23
Sec61 blockade by mycolactone: A central mechanism in Buruli ulcer disease. ( 30055020 )
2018
24
Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response. ( 30071818 )
2018
25
Improving clinical and epidemiological predictors of Buruli ulcer. ( 30080870 )
2018
26
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. ( 30102705 )
2018
27
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). ( 30136733 )
2018
28
Surgery for Buruli ulcer in the antibiotic era. ( 30152360 )
2018
29
Challenges associated with the treatment of Buruli ulcer. ( 30168876 )
2018
30
Implementing active community-based surveillance-response system for Buruli ulcer early case detection and management in Ghana. ( 30208037 )
2018
31
The association of rainfall and Buruli ulcer in southeastern Australia. ( 30222751 )
2018
32
Epidemiology of Buruli Ulcer Infections, Victoria, Australia, 2011-2016. ( 30334704 )
2018
33
Buruli ulcer in southern Côte D'ivoire: dynamic schemes of perception and interpretation of modes of transmission. ( 30376901 )
2018
34
Buruli Ulcer: a Review of the Current Knowledge. ( 30460172 )
2018
35
Treatment for Buruli ulcer: the long and winding road to antimicrobials-first. ( 30556580 )
2018
36
Draft Genome Sequence of Mycobacterium ulcerans S4018 Isolated from a Patient with an Active Buruli Ulcer in Benin, Africa. ( 28450515 )
2017
37
Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer. ( 28410412 )
2017
38
Evidences of the Low Implication of Mosquitoes in the Transmission of Mycobacterium ulcerans, the Causative Agent of Buruli Ulcer. ( 28932250 )
2017
39
Mycobacterium ulcerans DNA in Bandicoot Excreta in Buruli Ulcer-Endemic Area, Northern Queensland, Australia. ( 29148373 )
2017
40
Assessment of health care workers' knowledge, attitude and risk perception of Buruli ulcer disease in Southern Nigeria. ( 28957473 )
2017
41
Total Syntheses of Mycolactone A/B and its Analogues for the Exploration of the Biology of Buruli Ulcer. ( 29289244 )
2017
42
Global and local environmental changes as drivers of Buruli ulcer emergence. ( 28487559 )
2017
43
Bacterial diversity in Buruli ulcer skin lesions: Challenges in the clinical microbiome analysis of a skin disease. ( 28750103 )
2017
44
Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay. ( 28671942 )
2017
45
Mycobacterium ulcerans infection (Buruli ulcer) in French Guiana, South America, 1969-2013: an epidemiological study. ( 29851583 )
2017
46
Chronic cutaneous mycobacterial ulcers due to Mycobacterium ulcerans (Buruli ulcer): the first indigenous case report from Jordan and a literature review. ( 28344056 )
2017
47
Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms. ( 29046669 )
2017
48
Seasonal Pattern of Mycobacterium ulcerans, the Causative Agent of Buruli Ulcer, in the Environment in Ghana. ( 28238016 )
2017
49
Virulence potential of Staphylococcus aureus isolates from Buruli ulcer patients. ( 28442219 )
2017
50
Environmental and Behavioral Drivers of Buruli Ulcer Disease in Selected Communities Along the Densu River Basin of Ghana: A Case-Control Study. ( 28500810 )
2017

Variations for Buruli Ulcer

ClinVar genetic disease variations for Buruli Ulcer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SLC11A1 NM_000578.3(SLC11A1): c.1627G> A (p.Asp543Asn) single nucleotide variant risk factor rs17235409 GRCh37 Chromosome 2, 219259732: 219259732
2 SLC11A1 NM_000578.3(SLC11A1): c.1627G> A (p.Asp543Asn) single nucleotide variant risk factor rs17235409 GRCh38 Chromosome 2, 218395009: 218395009

Expression for Buruli Ulcer

Search GEO for disease gene expression data for Buruli Ulcer.

Pathways for Buruli Ulcer

Pathways related to Buruli Ulcer according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 CD40LG HBB IFNG IL10 IL4 SEC61A1
2
Show member pathways
12.43 CD40LG IFNG IL10 IL4
3 12.35 CD40LG IFNG IL10 IL4
4
Show member pathways
12.01 CD40LG IFNG IL10 IL4
5 11.8 IFNG IL10 IL4
6
Show member pathways
11.76 CD40LG IFNG IL10 IL4 WAS
7 11.63 IFNG WAS WASL
8 11.59 IFNG IL10 IL4
9
Show member pathways
11.55 CD40LG IFNG IL4
10 11.5 IFNG IL10 IL4
11 11.43 CD40LG IL10 IL4
12 11.24 IFNG IL10 IL4
13 11.1 IFNG IL4
14 11.09 HBB IFNG IL10
15 11.06 CD40LG IL4
16 11.02 CD40LG IFNG IL4
17 10.98 CD40LG IL10 IL4
18 10.9 IFNG IL10 IL4
19 10.75 IFNG IL10 IL4
20 10.61 CD40LG HBB IFNG IL10

GO Terms for Buruli Ulcer

Cellular components related to Buruli Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 actin cortical patch GO:0030479 8.62 WAS WASL

Biological processes related to Buruli Ulcer according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.93 ATF4 IL10 IL4 SLC11A1 WAS WASL
2 regulation of signaling receptor activity GO:0010469 9.85 CD40LG IFNG IL10 IL4
3 positive regulation of gene expression GO:0010628 9.84 ATF4 IFNG IL4 SLC11A1
4 B cell differentiation GO:0030183 9.61 CD40LG IL10 IL4
5 actin filament polymerization GO:0030041 9.58 WAS WASL
6 positive regulation of interleukin-12 production GO:0032735 9.57 CD40LG IFNG
7 response to interferon-gamma GO:0034341 9.56 SEC61A1 SLC11A1
8 actin filament-based movement GO:0030048 9.52 WAS WASL
9 defense response to protozoan GO:0042832 9.51 IL10 SLC11A1
10 actin polymerization or depolymerization GO:0008154 9.49 WAS WASL
11 positive regulation of actin nucleation GO:0051127 9.48 WAS WASL
12 positive regulation of Arp2/3 complex-mediated actin nucleation GO:2000601 9.4 WAS WASL
13 positive regulation of MHC class II biosynthetic process GO:0045348 9.37 IL10 IL4
14 actin cortical patch assembly GO:0000147 9.32 WAS WASL
15 actin cortical patch localization GO:0051666 9.26 WAS WASL
16 regulation of isotype switching GO:0045191 9.16 IL10 IL4
17 immune response GO:0006955 9.1 CD40LG IFNG IL10 IL4 SLC11A1 WAS
18 type 2 immune response GO:0042092 8.96 IL10 IL4

Molecular functions related to Buruli Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTPase regulator activity GO:0030695 8.96 WAS WASL
2 cytokine activity GO:0005125 8.92 CD40LG IFNG IL10 IL4

Sources for Buruli Ulcer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....